These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
    Author: Alacacioğlu I, Ozcan MA, Alacacioğlu A, Polat M, Yüksel F, Demirkan F, Pişkin O, Ozgenç Y, Ozsan HG, Undar B.
    Journal: Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211.
    Abstract:
    To explain the pathogenesis of preeclampsia with coagulation induction or a defective fibrinolysis, various hemostatic parameters were studied and different treatment modalities targeting these parameters were evaluated. Considering the role of TAFI in down-regulation of fibrinolysis, in our study we have investigated whether TAFI contributes to impaired fibrinolysis in patient with preeclampsia. Thirty patients with preeclampsia (mean age +/- SD 25.7 +/- 4.53; range 17-36) and 30 normal pregnant women as control group (mean age +/- SD 28 +/- 5.26; range 21-38) were included in our study. TAFI antigen was determined using an ELISA kit for quantitative measurement. The mean TAFI antigen levels were 12.55 +/- 1.88 microg/ml in patients with preeclampsia and 12.29 +/- 3.0 microg/ml in normal pregnant women. A statistically significant difference was not found between TAFI antigen levels of two groups (p > 0.05). In order to clarify the role of TAFI in the pathogenesis of preeclampsia, in addition to plasma TAFI levels, its synthesis, activation and metabolism should also be evaluated.
    [Abstract] [Full Text] [Related] [New Search]